Companies › PharmaIN
1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Terlipressin (PHIN-214) Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent | AVPR1A, AVPR1B, AVPR2 | Phase 1 | Cirrhosis, Liver | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05490888 | Terlipressin (PHIN-214) | Phase 1 | Cirrhosis, Liver | Gastroenterology | May 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.